In a world where everyone wants to be cured of disease and everyone who participates in the cure wants to get paid, the employer will feel the squeeze. (Photo: Shutterstock)
Drug matching services offered by genomics companies are emerging that can more accurately prescribe medications for chronically ill patients. The implications for employers who provide health insurance for large employee groups are cause for optimism: Money now misspent on drugs for plan members that aren't helping them will be saved, while those same patients will get healthier once they are on the correct medications.
But not all genetic innovations will have such win-win outcomes for plan sponsors. Researchers are beginning to spin out genetically based therapies that can alter a person's genetic makeup and, in so doing, prevent or cure previously deadly conditions. But these therapies will costs hundreds of thousands of dollars per patient. And the question facing payers is: Who will pay, and how will that who pay it?
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.